Overactive Bladder
Real-World Compliance with Percutaneous Tibial Nerve Stimulation Maintenance Therapy in an American Population.
February 14, 2021
Patient preference elicitation instrument, OABCare, to facilitate shared decision-making in the care of overactive bladder.
February 14, 2021
Considering non-bladder etiologies of overactive bladder: A functional neuroimaging study.
February 7, 2021
Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options.
February 7, 2021
Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia.
February 7, 2021
Potential Role of Monocyte Chemoattractant Protein-1 in Monitoring Disease Progression and Response to Treatment in Overactive Bladder Patients.
January 10, 2021
Clinical Manifestations of Overactive Bladder With Migraine as a Comorbidity: A Prospective Cross-Sectional Study.
January 10, 2021
Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men.
January 10, 2021
GEMTESA® (vibegron) Receives U.S. FDA Approval for the Treatment of Patients with Overactive Bladder (OAB)
January 4, 2021